InsidersTradesSigma
Track the DICE Therapeutics, Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, DICE Therapeutics, Inc. has logged 28 public disclosures. The latest transaction was reported on 9 August 2023 (Disposition). Among the most active insiders: Scopa James Paul. Every trade is free.
28
Insider Decl.
n/a
Thresholds
€71m
4 ops.
Buy Volume
€89m
16 ops.
Sell Volume
48Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 9 August 2023
Declarations28 total
147,497 sharesCommon StockSEC:0001209191-23-045171:0
49,841 sharesCommon StockSEC:0001209191-23-045194:0
8,427 sharesCommon StockSEC:0001209191-23-045175:0
7,070,205 sharesCommon StockSEC:0001104659-23-089351:0
15,199 sharesCommon StockSEC:0001209191-23-045182:0
152,285 sharesCommon StockSEC:0001209191-23-045173:0
799,685 sharesCommon StockSEC:0001209191-23-045172:0
198,000 sharesCommon StockSEC:0001209191-23-045180:0
220 shares0Common StockSEC:0001209191-23-044546:0
2,200 shares0Common StockSEC:0001209191-23-042750:0
300 shares0Common StockSEC:0001209191-23-042235:0
1,969,368 shares@ US$46.50100.0% of flowCommon StockSEC:0000899243-23-016413:0
14,307 shares@ US$30.3145.4% of flowCommon StockSEC:0001209191-23-034096:0
84,097 shares@ US$38.5056100.0% of flowCommon StockSEC:0001209191-23-028355:0
13,698 shares@ US$36.50100.0% of flowCommon StockSEC:0001209191-23-027770:0
18,750 shares@ US$36.552100.0% of flowCommon StockSEC:0001209191-23-027790:0
10,000 shares@ US$36.5398100.0% of flowCommon StockSEC:0001209191-23-027782:0
6,923 shares0Common StockSEC:0001209191-23-026618:0
16,392 shares@ US$30.083450.6% of flowCommon StockSEC:0001209191-23-024918:0
773 shares@ US$30.002.4% of flowCommon StockSEC:0001209191-23-022874:0
246,779 shares@ US$29.249.3% of flowCommon StockSEC:0001104659-23-039250:0
Canonical exit: 26 Jun 2023 (T+90)
500 shares@ US$30.08831.6% of flowCommon StockSEC:0001209191-23-021615:0
155,089 shares@ US$26.675.3% of flowCommon StockSEC:0001104659-23-037172:0
Canonical exit: 21 Jun 2023 (T+90)
30,719 shares0Common StockSEC:0001209191-23-020299:0
1,640,000 shares@ US$36.5085.3% of flowCommon StockSEC:0001104659-22-110000:0
Canonical exit: 15 Jan 2023 (T+90)
25 of 28 declarations
关于 DICE Therapeutics, Inc.
DICE Therapeutics, Inc. 是一家总部位于美国的生物制药公司，专注于发现和开发用于治疗炎症和免疫疾病的新型口服疗法。在被收购之前，该公司在纳斯达克上市，总部位于美国核心生物技术集群加利福尼亚州南旧金山。该公司通过首次公开募股从 DiCE Molecules Holdings, LLC 发展为 DICE Therapeutics, Inc.，其业务围绕一个名为 DELSCAPE 的专有发现引擎构建，该引擎旨在识别能够以类似生物制剂的效力调节蛋白质-蛋白质相互作用的选择性口服小分子。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1645569/000095017023008119/dice-20221231.htm?utm_source=openai)) 从运营角度来看，DICE 是一家临床阶段的生物技术公司，而不是商业阶段的制药公司。在独立运营时，它没有获批产品或产品收入。其主要战略重点是口服 IL-17 抑制剂，这是免疫学中一个重要的已验证靶点。这种定位具有商业吸引力，因为该公司试图解决一个主要的市场需求：提供注射生物制剂的口服替代品，可能提高便利性、依从性和患者可及性。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1645569/000156459021056499/dice-10q_20210930.htm?utm_source=openai)) 在竞争方面，DICE 因将小分子化学应用于通常由抗体和其他生物制剂主导的靶点而脱颖而出。这个差异化的平台是其关键资产，也是其投资案例的基础。与此同时，该公司也承担着早期和中期生物技术公司的典型风险：巨额运营亏损、对外部资本的依赖以及其价值取决于临床成功、监管进展和最终商业化的管线。SEC 文件显示，该公司在开发过程中积累了巨额亏损。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1645569/000095017023021193/dice-20230331.htm?utm_source=openai)) 最近最重要的进展是该公司被礼来公司收购。2023 年 6 月，礼来公司宣布达成最终协议，以约 2.4 billion 美元收购 DICE，突显了 DICE 的口服免疫学管线和技术平台。礼来公司于 2023 年 8 月 9 日完成了此次收购。对于查阅 Form 4 内部交易数据或历史 SEC 文件的投资者而言，关键在于 DICE Therapeutics 今天已不再是一家独立的上市公司；它已整合到礼来公司，尽管其历史文件仍保留在 SEC 记录中。（[investor.lilly.com](https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-dice-therapeutics-advance-innovation-immunology?utm_source=openai))
